-
RETHINKING HEALTH ECONOMIC MODELS FOR OUTCOME-ALIGNED PAYMENTS: A FRAMEWORK FOR THE NEW 2026 CMS ACCESS MODEL
Mar 18, 2026, 21:38 PM -
PSYCHOSOCIAL CORRELATES OF HEALTH ANXIETY IN A HEALTHY ADULT POPULATION
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF NOVEL ANDROGEN RECEPTOR INHIBITORS IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: A U.S. ANALYSIS INCORPORATING TWO-WAY SENSITIVITY ASSESSMENT
Mar 18, 2026, 21:38 PM -
CHARACTERIZING REAL-WORLD DISEASE BURDENS IN CARDIAC AMYLOIDOSIS: A DESCRIPTIVE STUDY ON SOCIAL, ECONOMIC, AND ACCESS-RELATED IMPACTS ON PATIENTS IN GERMANY AND SPAIN
Mar 18, 2026, 21:38 PM -
SPILLOVER EFFECTS OF US MFN POLICY ON EUROPEAN DRUG ACCESS
Mar 18, 2026, 21:38 PM -
ECONOMIC EVALUATION OF SACITUZUMAB GOVITECAN AMONG METASTATIC TRIPLE-NEGATIVE BREAST CANCER PATIENTS: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
TIMING OF ADJUVANT THERAPY AND TOTAL HEALTHCARE EXPENDITURES FOLLOWING ROBOTIC-ASSISTED LOBECTOMY OF NON-SMALL CELL LUNG CANCER: A SEER-MEDICARE ANALYSIS
Mar 18, 2026, 21:38 PM -
DISEASE PERCEPTION, QUALITY OF LIFE, AND MENTAL HEALTH OF NEWLY DIAGNOSED AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)-ELIGIBLE MULTIPLE MYELOMA PATIENTS FROM A TERTIARY CARE HOSPITAL IN CHINA: A CROSS-SECTIONAL SURVEY STUDY
Mar 18, 2026, 21:38 PM -
OPERATING ROOM EFFICIENCY AND COST IMPLICATIONS OF THULIUM FIBER LASER VERSUS HOLMIUM:YAG LASER FOR PROSTATE ENUCLEATION: A TARGETED REVIEW, ANALYSIS, AND MODEL
Mar 18, 2026, 21:38 PM -
WHO IS MOST AT RISK OF UNRECOGNIZED DIABETES? A STUDY TO INFORM PHARMACIST ACTION
Mar 18, 2026, 21:38 PM -
ACCEPTABILITY, PERCEPTIONS, AND BARRIERS TO VASECTOMY ACCESS IN LATIN AMERICA: A SYSTEMATIC REVIEW INFORMING POLICY AND HEALTH SYSTEM ACTION
Mar 18, 2026, 21:38 PM -
AI ENABLED RWE CODE REFACTORING OF ANALYTICS PIPELINE
Mar 18, 2026, 21:38 PM -
REAL WORLD HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH PANCREATIC CANCERIN THE BRAZILIAN PRIVATE MARKET
Mar 18, 2026, 21:38 PM -
VALIDATING PRIMARY AND SECONDARY HEALTHCARE RESOURCE USE AND COSTS ESTIMATES IN OMOP-MAPPED VS SOURCE CPRD-HES DATA IN THE UK
Mar 18, 2026, 21:38 PM -
PATIENT-REPORTED EXPERIENCES WITH CANCER-RELATED FATIGUE (CRF) FOLLOWING TREATMENT WITH CAR T-CELL THERAPY (CAR-T) IN PATIENTS WITH LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN
Mar 18, 2026, 21:38 PM -
DELAYS AND DENIALS FOR BRANDED MEDICATION FILLS DUE TO PRIOR AUTHORIZATION
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS OF RECURRENT STROKES IN MEDICARE FEE-FOR-SERVICE BENEFICIARIES IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
RISING PLASMA COLLECTION COSTS VS. IRA/MFN PRICE CONSTRAINTS: USING A PLASMA COLLECTION COST INDEX TO ASSESS RISKS TO IG SUPPLY
Mar 18, 2026, 21:38 PM -
COMPARATIVE ANALYSIS OF GENE THERAPIES AUTHORIZED BY THE U.S. FOOD AND DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
Mar 18, 2026, 21:38 PM
